CRMD News and Press, CorMedix Inc. From 07/26/23

BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report ...

2023-06-29 12:22:46 ET Shares of CorMedix (NASDAQ: CRMD) were down more than 21% as of noon ET on Thursday. The shares fell after the company announced a stock sale. The healthcare stock is down more than 5% so far this year. The stock sale was actually a double whammy of di...

2023-06-29 10:10:59 ET Gainers: RenovoRx ( RNXT ) +37% . Immunome ( IMNM ) +36% .  DermTech ( DMTK ) +15% . Galera Therapeutics ( GRTX ) +9% . Oncolytics Biotech ( ONCY ) +7% . Losers: BioXcel Therapeutics ( BTA...

2023-06-29 08:47:24 ET BioXcel Therapeutics ( BTAI ) -67% . announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation . CorMedix ( CRMD ) -21% on pricing $40M securities off...

2023-06-29 03:12:48 ET CorMedix ( NASDAQ: CRMD ) prices an underwritten public offering of 7.5 million common stock at a public offering price of $4.00 per share and pre-funded warrants to purchase ~2.5M shares of its common stock at a price of $3.999 per pre-funded warrant...

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previ...

2023-06-28 16:32:45 ET CorMedix ( NASDAQ: CRMD ) intends to conduct an underwritten public offering of common stock and pre-funded warrants, the company said Wednesday. Shares -16.6% at $4.23 afterhours. The company said it will be selling all of the shares and...

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that it intends to offer...

2023-06-21 12:48:11 ET CorMedix ( NASDAQ: CRMD ) said that the US Food and Drug Administration has accepted its resubmitted new drug application for DefenCath, with the agency expected to decide on whether to approve the product by Nov. 15. The company is seeking to have Defen...

BERKELEY HEIGHTS, N.J. , June 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced its first-of-kind strat...